Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)
Close on Nov 17, 2026Market cap $433.56MP/E –Yield –
Ovid Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Ovid Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$58.28M. For fiscal 2025 it was -$42.17M. The highest annual figure on record is $124.45M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$42.17M | – |
| FY2024 | Dec 31, 2024 | -$61.27M | – |
| FY2023 | Dec 31, 2023 | -$58.71M | – |
| FY2022 | Dec 31, 2022 | -$55.04M | -144.2% |
| FY2021 | Dec 31, 2021 | $124.45M | – |
| FY2020 | Dec 31, 2020 | -$81.12M | – |
| FY2019 | Dec 31, 2019 | -$61.15M | – |
| FY2018 | Dec 31, 2018 | -$52.79M | – |
| FY2017 | Dec 31, 2017 | -$64.93M | – |
| FY2016 | Dec 31, 2016 | -$22.48M | – |
| FY2015 | Dec 31, 2015 | -$13.18M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.81M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.97M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.06M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.88M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.04M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.99M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.65M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.19M | -109.2% |
| Q4 FY2021 | Dec 31, 2021 | -$26.30M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.63M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.26M | – |
| Q1 FY2021 | Mar 31, 2021 | $176.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.51M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$23.06M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.21M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.71M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.25M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.98M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.07M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.14M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.18M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.40M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.03M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.39M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.27M | – |
| Q1 FY2017 | Mar 31, 2017 | -$34.24M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.56M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.81M | – |
See a number that looks wrong?